Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 4/2018

01-08-2018 | Case Report

Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma

Authors: Ryosuke Kochi, Satoshi Yajima, Tatsuki Nanami, Takashi Suzuki, Yoko Oshima, Natsuki Tokura, Jun Takatsuka, Kimihiko Funahashi, Naobumi Tochigi, Hideaki Shimada

Published in: Clinical Journal of Gastroenterology | Issue 4/2018

Login to get access

Abstract

Serum p53 antibody (s-p53-Ab) titers were postoperatively monitored for over 5 years in a 67-year-old man with locally advanced esophageal squamous cell carcinoma. The tumor stage was classified as clinical stage II (cT3N0M0). Serum SCC antigen (s-SCC-Ag; 6.2 ng/mL) and s-p53-Ab (3.83 U/mL) were noted to be positive before surgery. Radical esophagectomy with three-field lymph node dissection was performed without neoadjuvant therapy. Pathological findings of the surgically resected specimens revealed a stage II tumor (pT3N0M0). Postoperatively, the patients did not receive any adjuvant therapy. Although the s-SCC-Ag was found to be negative at 2 months postoperatively, s-SCC-Ag was found to be six times positive despite no signs of recurrence. The s-p53-Ab titers constantly decreased to less than the cutoff value at 6 months postoperatively and continuously decreased over 5 years postoperatively. Finally, s-p53-Ab titers became less than the detection limit value at 60 months postoperatively. No recurrence was observed throughout the postoperative course. This case report is the first to describe the five-year monitoring of postoperative changes in s-p53-Ab titers in a patient with locally advanced esophageal squamous cell carcinoma without recurrence. s-p53-Ab titers seemed to be more useful than s-SCC-Ag for disease monitoring in this case.
Literature
1.
go back to reference Shimada H, Yajima S, Oshima Y, et al. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2014;9:131–40.CrossRef Shimada H, Yajima S, Oshima Y, et al. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2014;9:131–40.CrossRef
2.
go back to reference Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed
3.
go back to reference Saito F, Shimada H, Ogata H, et al. Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody. Esophagus. 2017;1:1–4. Saito F, Shimada H, Ogata H, et al. Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody. Esophagus. 2017;1:1–4.
4.
go back to reference Yamashita K, Makino T, Tanaka K, et al. Peritherapeutic serum p53 antibody titers are predictors of survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy and surgery. World J Surg. 2017;41:1566–74.CrossRefPubMed Yamashita K, Makino T, Tanaka K, et al. Peritherapeutic serum p53 antibody titers are predictors of survival in patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy and surgery. World J Surg. 2017;41:1566–74.CrossRefPubMed
5.
go back to reference Hiyoshi Y, Yoshida N, Watanabe M, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) in esophageal squamous cell carcinoma. World J Surg. 2017;41:480–6.CrossRefPubMed Hiyoshi Y, Yoshida N, Watanabe M, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) in esophageal squamous cell carcinoma. World J Surg. 2017;41:480–6.CrossRefPubMed
6.
go back to reference Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.CrossRefPubMed Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.CrossRefPubMed
7.
go back to reference Murayama K, Nanami T, Suzuki T, et al. Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery. Clin J Gastroenterol. 2017;24:1–4. Murayama K, Nanami T, Suzuki T, et al. Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery. Clin J Gastroenterol. 2017;24:1–4.
8.
go back to reference Kubota Y, Shimada H, Magoshi S, et al. Serum p53 antibody is a useful biomarker for long-term monitoring of breast cancer: report of a recurrent case after surgery. Toho J Med. 2016;2:22–5. Kubota Y, Shimada H, Magoshi S, et al. Serum p53 antibody is a useful biomarker for long-term monitoring of breast cancer: report of a recurrent case after surgery. Toho J Med. 2016;2:22–5.
9.
go back to reference Shimada H, Ochiai T, Nomura F, et al. Titration of serum p53 antibodies in 1,085 patient with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMed Shimada H, Ochiai T, Nomura F, et al. Titration of serum p53 antibodies in 1,085 patient with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMed
10.
go back to reference Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.CrossRefPubMed Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.CrossRefPubMed
Metadata
Title
Five-year postsurgical monitoring of serum p53 antibody for locally advanced esophageal squamous cell carcinoma
Authors
Ryosuke Kochi
Satoshi Yajima
Tatsuki Nanami
Takashi Suzuki
Yoko Oshima
Natsuki Tokura
Jun Takatsuka
Kimihiko Funahashi
Naobumi Tochigi
Hideaki Shimada
Publication date
01-08-2018
Publisher
Springer Japan
Published in
Clinical Journal of Gastroenterology / Issue 4/2018
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-018-0839-3

Other articles of this Issue 4/2018

Clinical Journal of Gastroenterology 4/2018 Go to the issue